Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug

Dow Jones

2025/10/30

By Adriano Marchese

Tectonic Therapeutic shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure.

Shares traded 23% higher ahead of the opening bell at $22.90.

Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics.

TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance.

Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 30, 2025 08:25 ET (12:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579149718"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579149718\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579149718?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579149718","market":"sg","top_or_hot":-1,"title":"Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TECX\">Tectonic Therapeutic</a> shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure. \n</p>\n<p>\n  Shares traded 23% higher ahead of the opening bell at $22.90. \n</p>\n<p>\n  Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics. \n</p>\n<p>\n  TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance. \n</p>\n<p>\n  Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 08:25 ET (12:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTectonic Therapeutic Shares Rise in Premarket on Positive Data for XT45 Drug\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-30 20:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TECX\">Tectonic Therapeutic</a> shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure. \n</p>\n<p>\n  Shares traded 23% higher ahead of the opening bell at $22.90. \n</p>\n<p>\n  Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics. \n</p>\n<p>\n  TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance. \n</p>\n<p>\n  Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 08:25 ET (12:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579149718","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579149718","pubTimestamp":1761827100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tectonic Therapeutic shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure.Shares traded 23% higher ahead of the opening bell at $22.90.Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics.TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance.Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TECX":"Tectonic Therapeutic, Inc."},"translate_title":"由于XT45药物的积极数据，Tectonic Therapeutic股价在盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECX":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\nTectonic Therapeutic shares jumped in premarket trading Thursday after the company reported positive trial data for its treatment of pulmonary hypertension and heart failure. \n\n\n  Shares traded 23% higher ahead of the opening bell at $22.90. \n\n\n  Data from the phase 1b part B acute hemodynamic clinical trial showed that a single intravenous dose of its TX45 drug was well tolerated and brought on meaningful improvements in both left heart function and pulmonary hemodynamics. \n\n\n  TX45 is Tectonic's new drug that aims to improve heart and lung function in patients with group 2 pulmonary hypertension and heart failure. This condition involves elevated blood pressure in the lungs due to left heart disease, leading to poor heart and lung performance. \n\n\n  Tectonic also noted that there were no serious health issues and the drug was well tolerated among the cohort of patients. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 08:25 ET (12:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}